Emergent Biosolutions PE Ratio 2007-2021 | EBS

Current and historical p/e ratio for Emergent Biosolutions (EBS) from 2007 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Emergent Biosolutions PE ratio as of January 27, 2022 is 8.56.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Emergent Biosolutions PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-01-27 44.24 10.53
2021-09-30 50.07 $4.20 11.92
2021-06-30 62.99 $5.54 11.37
2021-03-31 92.91 $7.18 12.94
2020-12-31 89.60 $5.66 15.83
2020-09-30 103.33 $3.11 33.23
2020-06-30 79.08 $3.21 24.64
2020-03-31 57.86 $1.30 44.51
2019-12-31 53.95 $1.03 52.38
2019-09-30 52.28 $0.07 746.86
2019-06-30 48.31 $-0.35 0.00
2019-03-31 50.52 $0.81 62.37
2018-12-31 59.28 $1.22 48.59
2018-09-30 65.83 $1.96 33.59
2018-06-30 50.49 $2.23 22.64
2018-03-31 52.65 $1.36 38.71
2017-12-31 46.47 $1.69 27.50
2017-09-30 40.45 $1.69 23.93
2017-06-30 33.91 $1.46 23.23
2017-03-31 29.04 $1.08 26.89
2016-12-31 32.84 $0.95 34.57
2016-09-30 31.53 $0.99 31.85
2016-06-30 26.35 $1.33 19.81
2016-03-31 34.06 $1.92 17.74
2015-12-31 37.49 $1.25 29.99
2015-09-30 26.70 $1.20 22.25
2015-06-30 30.88 $0.90 34.31
2015-03-31 26.95 $0.71 37.96
2014-12-31 25.52 $0.73 34.95
2014-09-30 19.97 $0.48 41.60
2014-06-30 21.05 $0.35 60.13
2014-03-31 23.68 $0.51 46.43
2013-12-31 21.54 $0.84 25.65
2013-09-30 17.85 $0.87 20.52
2013-06-30 13.51 $0.69 19.58
2013-03-31 13.10 $0.61 21.47
2012-12-31 15.03 $0.64 23.48
2012-09-30 13.32 $0.98 13.59
2012-06-30 14.20 $0.84 16.90
2012-03-31 14.99 $1.02 14.70
2011-12-31 15.78 $0.60 26.30
2011-09-30 14.46 $0.58 24.93
2011-06-30 21.13 $0.95 22.24
2011-03-31 22.64 $0.87 26.02
2010-12-31 21.98 $1.56 14.09
2010-09-30 16.17 $0.93 17.39
2010-06-30 15.31 $0.55 27.84
2010-03-31 15.73 $0.72 21.85
2009-12-31 12.73 $0.99 12.86
2009-09-30 16.55 $0.91 18.18
2009-06-30 13.43 $1.22 11.01
2009-03-31 12.66 $0.80 15.82
2008-12-31 24.47 $0.69 35.46
2008-09-30 12.27 $1.57 7.81
2008-06-30 9.30 $1.33 7.00
2008-03-31 8.36 $1.10 7.60
2007-12-31 4.74 $0.76 6.24
2007-09-30 8.32 $-0.17 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.380B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88